The company has achieved proof of concept and produced Germ Free eggs from three generations of Germ Free birds. The company has built a state-of-the-art avian facility on its seven acre site which will be used to produce the initial flocks of Germ Free birds and Germ Free eggs for customer evaluation and viral yield analysis. Plans are in place to build two additional Germ Free production facilities and a logistics building, to scale up production and commercialise the business.
This will enable the production of 4 million Germ Free eggs from our Irish site.
This will then trigger our larger market scale up with satellite facilities placed globally close to large egg based vaccine manufacturers.
To produce Germ Free eggs on a large-scale, Ovagen will use biosafety decontamination techniques and best-practice poultry husbandry methods meeting directive 2010/63/EU
Sectors Targeted:
-
- Vaccine Industry
- Research Institutes
- Diagnostic
- Pharmaceutical
- Biopharma
